Article
Oncology
Dae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae-Yong Kim, Sae-Won Han, Youn Oh, Seock-Ah Im, Tae-You Kim, Youngeun Lee, Haeryoung Kim, Kyung-Hun Lee
Summary: This study demonstrated that avelumab had moderate efficacy and good tolerability in patients with advanced hepatocellular carcinoma previously treated with sorafenib. The duration of sorafenib treatment prior to avelumab therapy appeared to influence the treatment outcomes.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giovanni Giannini, Sara Marinelli, Gian Ludovico Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Giuseppe Foschi, Marco Zoli, Antonio Gasbarrini, Gianluca Svegliati Baroni, Alberto Masotto, Rodolfo Sacco, Giovanni Raimondo, Francesco Azzaroli, Andrea Mega, Gianpaolo Vidili, Maurizia Rossana Brunetto, Gerardo Nardone, Luigina Vanessa Alemanni, Elton Dajti, Federico Ravaioli, Davide Festi, Franco Trevisani
Summary: This study aimed to identify simple demographic and clinical parameters to predict survival and Sorafenib response in patients with advanced hepatocellular carcinoma. The results showed that patient's general status, liver function, laboratory parameters, and HCC aggressiveness were associated with the outcome of Sorafenib therapy. Two predictive nomograms were created to assist clinicians in therapeutic choices.
Article
Multidisciplinary Sciences
Shou-Sheng Chu, Yu-Hsuan Kuo, Wen-Shan Liu, Shih-Chang Wang, Chung-Han Ho, Yi-Chen Chen, Ching-Chieh Yang, Hung-Chang Wu
Summary: The combination of sorafenib and radiotherapy can increase survival rates for advanced hepatocellular carcinoma patients, particularly when radiotherapy is administered after sorafenib treatment.
SCIENTIFIC REPORTS
(2021)
Review
Gastroenterology & Hepatology
Paul J. Thuluvath, Chau To, Waseem Amjad
Summary: Hepatocellular cancer is a common and deadly cancer worldwide. Liver transplantation is the preferred treatment for unresectable HCC, but due to long waiting periods, locoregional therapies may be needed for some patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Xin Li, Yaxi Wang, Xin Ye, Ping Liang
Summary: Despite advances in antiviral drugs and surveillance tools, the number of late-stage hepatocellular carcinoma patients with poor prognosis is increasing. Systemic treatment with tyrosine kinase inhibitors (TKIs) has been widely used for a decade, but combining them with other compounds like immune checkpoint inhibitors and antiangiogenic inhibitors may offer more effective treatment options. However, challenges including adverse effects, low response rates, and short survival highlight the need for novel or optimized therapies for advanced HCC.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Review
Gastroenterology & Hepatology
Cody R. Criss, Mina S. Makary
Summary: Hepatocellular carcinoma is the second leading cause of cancer-related death globally. Despite screening efforts and treatment algorithms, recurrence rates for the disease remain high. Unlike first-line treatment, there is no consensus or general recommendations for recurrent HCC. This review examines recent evidence on salvage loco-regional therapies for recurrent HCC after failed curative-intent.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Bohyun Kim, Soon Sun Kim, Sung Won Cho, Jae Youn Cheong, Jimi Huh, Jai Keun Kim, Jei Hee Lee, Hye Ri Ahn, Hyo Jung Cho
Summary: Liver stiffness quantified using magnetic resonance elastography is a potential biomarker for predicting poor overall survival and significant liver injury in advanced hepatocellular carcinoma patients treated with sorafenib.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Anna Soria, Mariona Calvo, Meritxell Casas, Zara Vidales, Sergio Munoz-Martinez, Victor Sapena, Marc Puigvehi, Lidia Canillas, Raquel Guardeno, Adolfo Gallego, Beatriz Minguez, Diana Horta, Ariadna Clos, Silvia Montoliu, Merce Roget, Maria Reig, Mercedes Vergara
Summary: This study characterized elderly patients treated with sorafenib and found that it is safe for this population. The findings provide valuable information for the use of atezolizumab-bevacizumab in elderly candidates.
FRONTIERS IN ONCOLOGY
(2022)
Review
Gastroenterology & Hepatology
Mina S. Makary, Stuart Ramsell, Eric Miller, Eliza W. Beal, Joshua D. Dowell
Summary: Hepatocellular carcinoma is the most common primary cancer of the liver with a low survival rate. Liver-directed locoregional therapies offer effective treatment options for patients with unresectable disease, with different goals based on disease stage. The review explores various therapies and prognostic factors for HCC.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Oncology
Perla Chami, William Jarnagin, Ghassan K. Abou-Alfa, James Harding, Neal Kim, Haibo Lin, Maria El Homsi, Christopher Crane, Carla Hajj
Summary: Ablation, arterially directed therapies and external beam radiation therapy are considered for HCC patients who are not eligible for transplant or resection. Combinations of these therapies with systemic drugs are being studied for better therapeutic outcomes. This review provides an up-to-date overview of current and developing treatment modalities for HCC.
Article
Oncology
Qinqin Liu, Nan You, Jing Li, Ke Wu, Xuehui Peng, Zheng Wang, Liang Wang, Yinan Zhu, Lu Zheng
Summary: The study found that the combination of camrelizumab and sorafenib significantly improved the overall response rate and progression-free survival of patients with advanced HCC, but had no significant impact on overall survival. The combination therapy group exhibited more adverse events in terms of efficacy, but most of these adverse events were easily controlled after treatment. Further prospective randomized trials are needed to confirm the potential clinical benefits of this combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann-Lii Cheng, Andrew X. Zhu
Summary: This study reports the long-term efficacy and safety of pembrolizumab, a PD-1 inhibitor, in patients with advanced hepatocellular carcinoma. The results demonstrate durable anti-tumor activity of pembrolizumab in these patients, with a favorable safety profile.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Daniela Reis, Miguel Moura, Luis Carlos Freitas, Sofia Carvalhana, Paulo Jorge Nogueira, Raquel Gaio, Rui Tato Marinho, Helena Cortez-Pinto
Summary: A retrospective study of 77 advanced hepatocellular carcinoma patients found that Child-Pugh class A and absence of portal vein invasion were independent predictors of long-term survival. Sorafenib treatment can lead to over 2-year survival in a subgroup of patients.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Oncology
May Tun Saung, Lorraine Pelosof, Sandra Casak, Martha Donoghue, Steven Lemery, Mengdie Yuan, Lisa Rodriguez, Peter Schotland, Meredith Chuk, Gina Davis, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Lola Fashoyin-Aje
Summary: The FDA granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of HCC based on data from cohort 4 of Check-Mate 040, showing comparable BICR-assessed ORR in all three arms at 31%-32%. Adverse events were consistent with known profiles of nivolumab and ipilimumab, with no new safety events identified.
Article
Medicine, General & Internal
Guilherme Nader Marta, Leonardo G. da Fonseca, Maria Ignez Braghiroli, Fernando Moura, Paulo M. Hoff, Jorge Sabbaga
Summary: This study evaluated the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma, showing no significant differences in outcomes between younger and older patients. Age alone should not restrict clinical decision-making for patients with advanced HCC.
Article
Oncology
Ryan M. Rhome, Erin Moshier, Umut Sarpel, Nisha Ohri, Madhu Mazumdar, Michael H. Buckstein
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2017)
Letter
Oncology
Yaniv Berger, John H. Spivack, Marina Heskel, Samantha N. Aycart, Daniel M. Labow, Umut Sarpel
JOURNAL OF SURGICAL ONCOLOGY
(2017)
Article
Gastroenterology & Hepatology
Parissa Tabrizian, Yaniv Berger, Elisa Sefora Pierobon, Samantha Aycart, Pamela Argiriadi, Kezhen Fei, Gonzalo Carrasco-Avino, Daniel M. Labow, Umut Sarpel
Article
Gastroenterology & Hepatology
Jennifer M. Kolb, Pamela Argiriadi, Karen Lee, Xiaoyu Liu, Emilia Bagiella, Shivani Gupta, Aimee L. Lucas, Michelle Kang Kim, Nikhil A. Kumta, Satish Nagula, Umut Sarpel, Christopher J. DiMaio
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2018)
Article
Neurosciences
Greeshma Rajeev-Kumar, Umut Sarpel, Mandip S. Dhamoon
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
(2018)
Article
Oncology
Daniel Solomon, Natasha L. DeNicola, Yael Feferman, Eliahu Bekhor, Marina L. Reppucci, Daniela Feingold, Samantha N. Aycart, Deepa R. Magge, Benjamin J. Golas, Daniel M. Labow, Umut Sarpel
ANNALS OF SURGICAL ONCOLOGY
(2019)
Article
Oncology
Yael Feferman, Daniel Solomon, Shanel Bhagwandin, Joseph Kim, Samantha N. Aycart, Daniela Feingold, Umut Sarpel, Daniel M. Labow
ANNALS OF SURGICAL ONCOLOGY
(2019)
Article
Surgery
Daniel Solomon, Natasha Leigh, Eliahu Bekhor, Yael Feferman, Poojaben Dhorajiya, Daniela Feingold, Margaret Hofstedt, Samantha N. Aycart, Benjamin J. Golas, Umut Sarpel, Daniel M. Labow, Deepa R. Magge
Summary: This study retrospectively reviewed patients with peritoneal metastases of colorectal cancer who underwent CRS/HIPEC and found that mBRAF mutation was independently associated with earlier recurrence, leading to poor median DFS. Strict patient selection is advisable for these patients.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND
(2021)
Article
Medicine, Research & Experimental
Eric Pletcher, Elizabeth Gleeson, Tali Shaltiel, Natasha Leigh, Brianne Sullivan, Daniel Labow, Deepa Magge, Benjamin Golas, Noah Cohen, Umut Sarpel
Summary: The study found that the lymphocyte-to-monocyte ratio (LMR) can predict overall survival (OS) in patients with colorectal and appendiceal adenocarcinoma undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
BIOMARKERS IN MEDICINE
(2021)
Article
Health Policy & Services
Umut Sarpel, Marina Heskel, John Henry Spivack, Yael Feferman, Celina Ang, Francesca Gany
JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
(2018)
Article
Public, Environmental & Occupational Health
S. Fitzgerald, J. Chao, Y. Feferman, P. Perumalswami, U. Sarpel
JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES
(2017)
Correction
Public, Environmental & Occupational Health
S. Fitzgerald, J. Chao, Y. Feferman, P. Perumalswami, U. Sarpel
JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES
(2017)
Article
Oncology
Yael Feferman, Shanel Bhagwandin, Joseph Kim, Samantha N. Aycart, Daniela Feingold, Daniel M. Labow, Umut Sarpel
ANNALS OF SURGICAL ONCOLOGY
(2017)
Article
Oncology
Celina Ang, Aryeh Stollman, Hongfa Zhu, Umut Sarpel, Bethann Scarborough, Gagan Sahni, Sherri Z. Millis
CASE REPORTS IN ONCOLOGY
(2017)
Article
Health Policy & Services
Umut Sarpel, Xiaoxiao Huang, Charlotte Austin, Francesca Gany
JOURNAL OF COMMUNITY HEALTH
(2018)